Epsilogen: The Pioneer in Anti-cancer Antibodies
Epsilogen is a world pioneer in the creation of anti-cancer antibodies called immunoglobulin E (IgE). IgE has various characteristics that make it appropriate for treating solid tumors, including increased potency, improved tumor access, and a lengthy tissue half-life. IgE’s epsilon constant region binds extremely firmly to the FcRI receptor on the surface of immune effector cells such as macrophages, monocytes, basophils, and eosinophils. The bulk of IgE molecules are firmly bound to the surface of immune effector cells due to this contact, which is up to 10,000 times larger than the gamma chain of IgG possesses for its corresponding receptor. As a result, the latter is prepared and ready to attack cells that display the antigen that the IgE recognizes.
As a consequence, IgE is able to penetrate tissues more efficiently than IgG, resulting in much higher levels of ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the 2 significant methods by which immune effector cells destroy tumor cells. IgE also has a longer tissue half-life than IgG (2 weeks vs 2–3 days), which makes it a good candidate for destroying solid tumors.
The company’s flagship program targets the folate receptor alpha (FR alpha), and an anti-FR alpha IgE antibody is now being tested for ovarian cancer in a phase I study. This is the first IgE therapy to reach the clinic in the globe.
Epsilogen is also working on the IGEGTM platform, which combines the strengths of IgE and IgG antibody molecules.
In essence, the protein synthesis technology encompasses IgE evolved to kill multicellular tissue-dwelling parasites. Epsilogen is harnessing this power to kill solid tumors.
One thought on “Anti-cancer Antibodies by the Protein Synthesis Tech”